請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32485
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊立民 | |
dc.contributor.author | Yi-Cheng Chang | en |
dc.contributor.author | 張以承 | zh_TW |
dc.date.accessioned | 2021-06-13T03:52:13Z | - |
dc.date.available | 2006-08-02 | |
dc.date.copyright | 2006-08-02 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-26 | |
dc.identifier.citation | 1.Beg AA, Finco TS, Nantermet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Mol Cell Biol 1993; 13: 3301
2.Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauser M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin/PBEFconcentrations and fat-depot specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916. 3.Bottcher Y, Teupser, Enigk B, Berndt J, Kloting N, Schon MR, Bluher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin/PBEFgene (PBEF1) and its relation to glucose metabolism and fat depot specific mRNA expression in humans. J Clin Endocrin Metab 2006 (Epub ahead of print). 4.Bruton LL, Lazo JS, Parker KL. 2006 Goodman &Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; p 690 5.Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh G, Zucker JD, Basdevant A, Langin D, Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54: 2277-2286. 6.Chen MP, Chung FM, Chang DM Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299. 7.Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, Stich V, Cancello R, Langin D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18: 1657- 1669. 8.Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, Bouloumié A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747. 9.Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. Inter J Obes 2005; 27: 875-888. 10.Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 416-430. 11.Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564-1571. 12.Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin/PBEFrelease. Am J Physiol Endocrinol Metab 2006 (Epub ahead of print) 13.Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin/PBEFconcentration in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581. 14.Hammarstedt A, Pihlajamaki J, Sopasakis VR, Gogg S, Jansson PA, Laakso M, Smith U. Visfatin/PBEFis an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91: 1181-1184. 15.Jia SH, Li Y, Pirodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-27. 16.Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 74-78. 17.Kloting N, Kloting I. Visfatin: Gene expression in isolated adipocytes and sequence analysis in obese WORK rats compared with lean control rats. Biochem Biophysiol Res Com 2005; 332: 1070-1072. 18.Kryzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, Schernthaner G. Increased visfatin/PBEFconcentrations in women with gestational diabetes mellitus. Clin Sci 2006; 110: 605-609. 19.Li N, Karin M. Is NF-κB the sensor of oxidative stress ? FASEB J 1999; 13: 1137-1143 20.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419. 21.McEvoy GK 2006 AHFS Drug Information. In: Snow EK, Kester L, Litvak K, Miller J, Welsh OH, Jr, Mendham NA, O’Rourke A, eds. American Society of Health-System Pharmacists; p1997, 2010, 2049, 2063. 22.Moynihan KA, Grimn AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Meneur C, Permutt MA, Imai S. Increased dose of mammlian Sir2 in pancreatic beta cell enhanced glucose-induced insulin secretion in mice. Cell Metab 2005 2: 105-17. 23.Ognjanovic S, Bao S, Yamamoto SY, Tupas-Garibay J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression on human fetal membranes. J Mol Endocrinol 2001; 26: 107-17. 24.Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O. Changes in fat-derived hormones plasma concentrations: adiponectin, leptin, resistin, and visfatin/PBEFin rheumatoid arthritis subjects. Ann Rheuma Dis 2006 Jan 13 (Epub ahead of print) 25.Peterson KF, Dufour S, Befroy D, Garcin R, Shulman GI. 2004 Impaired mitochondrial activity on the insulin-resistant offspring of patients with type 2 diabetes. New Engl J Med 350: 664-71. 26.Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre B-cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006 (Epub ahead of print) 27.Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-3234. 28.Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437. 29.Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiuang CH, Sengchanthalangsy LL, Ghosh G, Glass CK. 15-deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 2000; 96: 4668-4673. 30.Stenphens JM, Vidal-Puig A. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opinion Lipdiol 2006; 17: 128-131. 31.Subrahmanyam YV, Yamaga S, Prashar Y, Lee HH, Hoe NP, Kluger Y, Gerstein M, Goguen JD, Newburger PE, Weissman SM. RNA expression patterns change dramatically in human neutrophil exposed to bacteria. Blood 2001; 97: 2457-68. 32.Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocyte and macrophages aggravated inflammatory changes – role of free fatty acids and tumor necrosis factors-α. Arterioscler Thromb Vasc Biol 2005; 25: 2062-2068. 33.Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in theroi ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1 and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247-9258. 34.van der Veer E, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering G. Pre-B-cell-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Cir Res 2005; 97: 25-34. 35.Weisber SP, McCann D, Desai M, Rosenbaum, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808. 36.Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol 2006 (Epub ahead of print) 37.Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increased plasma levels of an adipocyte-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001 86:3815-3819. 38.Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998; 396: 77-80. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32485 | - |
dc.description.abstract | 脂肪組織會產生許多分泌性物質, 稱為脂肪激素(adipokines), 在人體的能量新陳代謝中扮演重要角色。
最近, 以基因差異表現方法(differential display method)找尋到一種新的可能的脂肪激素, 稱為visfatin/PBEF。研究顯示visfatin/PBEF在人類和小鼠身體中, 主要是表現在內臟脂肪組織(visceral fat), 而非皮下脂肪組織(subcutaneous fat), 而且其血清濃度會隨著肥胖而增高。Visfatin/PBEF在週邊組織會和胰島素受器結合, 具有類似胰島素的作用, 可以降低血糖。 為了釐清visfatin/PBEF在人體內的作用, 我們利用定量即時聚合酶鍊反應(quantitative real-time polymerase chain reaction, RT-PCR), 測定62位臺灣成年人中, 腹部內臟脂肪組織及皮下脂肪組織中visfatin/PBEF mRNA表現量, 並研究其與新陳代謝表現型(metabolic phenotypes)的關連。 我們發現visfatin/PBEF mRNA表現量在皮下脂肪組織中較在內臟脂肪組織中高(以比較閾值次數值comparative threshold cycle values △Ct 表示: -0.75 ± 2.71 v.s. –1.36 ± 2.47; p= 0.04), 尤其是在肥胖的人身上 (△Ct: -0.53 ± 2.57 v.s. –1.46 ± 2.41; p= 0.006)。兩者和身體質量指數(body mass index)皆無相關。皮下脂肪組織中visfatin/PBEF mRNA和飯前血清中胰島素濃度呈現正相關(r= 0.40, p= 0.008), 和胰島素阻抗指標Homeostasis Model Assessment (HOMA-IR) 也呈現正相關(r= 0.35, p= 0.02)。 我們進一步利用小鼠RAW 267.4 巨噬細胞株以及3T3-L1脂肪細胞株(這兩種細胞為脂肪組織中兩種主要表現visfatin/PBEF的細胞類型)為模型, 釐清脂肪組織中visfatin/PBEF 蛋白質表現可能的調節機轉。我們發現長時間(96小時)的游離脂肪酸(free fatty acids), 包括palmitate和oleate, 會大量增加巨噬細胞visfatin/PBEF的表現, 同時也會增加iNOS表現。NF-κB 抑制劑 parthenolide會抑制此作用, 而NF-κB促進劑 lipopolysaccharide會增加visfatin/PBEF表現。依此推測, 游離脂肪酸可能會經由活化NF-κB 而增加visfatin/PBEF表現。 Aspirin 及sodium salicylate為已知具有抑制 NF-κB 活性之非類固醇抗發炎藥物, 也會抑制visfatin/PBEF在巨噬細胞的表現, 相反的, ketorolac或indomethacin等其他非類固醇抗發炎藥物則沒有此作用。15-deoxy-Δ12,14-prostaglandin J2 是已知具有抑制NF-κB 活化作用的內生性peroxisome proliferator-activated receptor-γ(PPAR-γ)促進劑, 也會抑制visfatin/PBEF在巨噬細胞的表現, 相反的, 合成PPAR-γ促進劑rosiglitazone則沒有此作用。 簡言之, 我們的研究顯示高胰島素阻抗性的人其腹部皮下脂肪組織visfatin/PBEF mRNA表現量增加, 這增加可能和脂肪組織內巨噬細胞受游離脂肪酸刺激而活化有關。 | zh_TW |
dc.description.abstract | Context: Visfatin/PBEF was recently identified as an adipocytokine predominantly expressed and secreted in visceral adipose tissue with insulin-mimetic effect in peripheral tissues.
Objectives: The goals were to investigate the association of visfatin/PBEF gene expresion in human abdominal adipose tissue with metabolic phenotypes and to identify the regulatory mechanism of visfatin/PBEF expression in cultured cells. Subjects and Methods: Relative visfatin/PBEF mRNA levels in human abdominal visceral and subcutaneous adipose tissues were determined by quantitative real-time polymerase chain reaction for correlation with metabolic phenotypes. Regulation of visfatin/PBEF expression by humoral factors was examined using cultured murine3T3-L1 adipocytes and RAW 264.7 macrophages. Results: Relative visfatin/PBEF mRNA levels in abdominal subcutaneous adipose tissue were higher than those in visceral adipose tissue and neither correlated with BMI. Relative visfatin/PBEF mRNA levels in abdominal subcutaneous adipose tissue correlated positively with fasting plasma insulin concentrations and with the insulin resistance index by Homeostasis Model Assessment(HOMA-IR). Free fatty acids (palmitate and oleate) and lipopolysaccharide stimulated visfatin/PBEF expression in RAW 264.7 macrophages but not 3T3-L1 adipocytes; the stimulation was mediated by NF-κB activation. Treatment with aspirin, sodium salicylate, or 15-deoxy-Δ12,14-prostaglandin J2 (15-d-PGJ2), but not indomethacin, ketorolac or rosiglitazone, suppressed visfatin/PBEF expression in RAW 264.7 macrophages. Conclusions: Visfatin/PBEF mRNA expression in abdominal subcutaneous adipose tissue is increased in hyperinsulinemic and insulin-resistant subjects. Visfatin/PBEF expression is induced by free fatty acids and inflammatory stimuli in macrophages rather than adipocytes. These findings support linkages among insulin resistance, macrophage activation, and increased visfatin/PBEF expression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T03:52:13Z (GMT). No. of bitstreams: 1 ntu-95-P93421031-1.pdf: 919854 bytes, checksum: a32164a994d259eff6d9c569f2ccccf7 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 口試委員, 指導教授與所長簽名………………………………………2
致謝………………………………………………………………………3 一、 中文摘要 (Abstract in Chinese)………………………5 二、 緒論 (Introduction)………………………………………6 三、 研究方法與對象 (Method and Subjects)………………8 四、 結果 (Results)…………………………………………10 五、 討論 (Discussion)………………………………………12 六、 侷限與展望 (Limitations and Perspective)…………15 七、 英文簡述 (Abstract in English)...…………………16 八、 英文論文 (English Manuscript)………………………18 九、 參考文獻 (References) …………………………………37 十、 圖表 (Figures and Tables)……………………………41 | |
dc.language.iso | zh-TW | |
dc.title | 人類腹部脂肪組織中visfatin/PBEF訊息核糖核酸表現量與新陳代謝表現型之關連以及其調節機轉 | zh_TW |
dc.title | Visfatin/PBEF mRNA Expression in Human Adipose Tissue:The Association with Metabolic Phenotypes And Its Regulatory Mechanism | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃天祥,江福田 | |
dc.subject.keyword | visfatin,PBEF,脂肪組織,巨噬細胞,游離脂肪酸,發炎, | zh_TW |
dc.subject.keyword | visfatin,PBEF,adipose tissue,macrophage,free fatty acid,inflammation, | en |
dc.relation.page | 50 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 898.29 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。